news
Longevica hires ex-Genentech exec to lead longevity drug development
Longevica, a longevity biotech firm, hired drug approval veteran Prasun Mishra as its new CEO. Mishra, formerly of Genentech, will steer the company's research toward clinical trials after their massive mammalian longevity screen concluded. This move signals a pivot from pure research to product development for human lifespan extension.
Longevica, a longevity biotech firm, hired drug approval veteran Prasun Mishra as its new CEO. Mishra, formerly of Genentech, will steer the company's research toward clinical trials after their massive mammalian longevity screen concluded. This move signals a pivot from pure research to product development for human lifespan extension.
The architecture take
This is how the longevity industry starts to get real. You spend $13 million and four years screening mice for drugs that extend life, and then you bring in the heavy hitters from pharma to actually get something through trials. It's a clear signal that Longevica isn't just playing in the academic sandbox anymore; they're aiming for a pill that hits a longevity mechanism in humans. Mishra’s background at Genentech means he knows what it takes to navigate the regulatory gauntlet. I'm watching to see what specific compounds emerge from that mouse screen, and more importantly, what pathway they plan to take to get those into our bodies. This move suggests we're inching closer to seeing 'longevity drugs' on pharmacy shelves, not just in labs. The question is which molecular pathway they'll double down on first.